Executing biomarker-driven oncology trials

Summary: Biomarker trials are changing how we treat cancer by matching the exact right drug to the right patient. Brant Nicks, an expert from a company called Allucent, explains that while this "precision medicine" is amazing, it is also incredibly hard to pull off. Because these trials look for very specific tumor markers, up to 80% of patients who get tested might not qualify for the study. This can be very frustrating for doctors and patients.

On top of that, the FDA has new rules. They want researchers to find the perfect, optimal dose instead of just the highest dose a patient can handle. They also require companies to track patients for 5 to 15 years to make sure they stay safe—even if the drug ends up failing! Despite the massive headaches and tiny patient pools, experts say the hard work is completely worth it because it is finally changing cancer survival rates for the better.

For more details, see Fierce Biotech at fiercebiotech.com/sponsored/executing-biomarker-driven-oncology-trials (opens in new tab)